Published Date: 17 Feb 2023
Bhopal: Over 10,000...
Read Full NewsPrime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing...
In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.
Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.
Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.
Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.
Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.
Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.
1.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
2.
From Pathology to Precision: The Story of Leukemia Therapy
3.
Reducing social media to an hour a day boosts young people's self-image.
4.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
5.
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.
1.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
2.
Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology
3.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
4.
Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment
5.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
Navigating the Complexities of Ph Negative ALL - Part VIII
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation